CH may treat inflammation and prevent fibrosis by decreasing the inflammatory response and fibrosis induced by TGF-β1 in synovial fibroblasts (SFs) via inhibiting thioredoxin-interacting protein (TXNIP)-NLRP3 interactions in TGF-β-induced SFs [51]. This evidence concerns the gene TGFB1 and cyclic hematopoiesis.